Pfizer (PFE) News Today $25.77 +0.21 (+0.81%) Closing price 03:59 PM EasternExtended Trading$25.80 +0.03 (+0.11%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Why Is Pfizer Up Today?Toggle Visibility of Why Is Pfizer Up Today?Pfizer Inc. (NYSE:PFE) shares have climbed today following a series of positive clinical trial readouts and encouraging pipeline updates across oncology, rare diseases and specialty care. Investors are optimistic about the Phase 3 EMBARK survival win for Xtandi in prostate cancer, as well as multiple “game-changer” studies in COVID-19 treatment, migraine and atopic dermatitis. Offsetting these gains are ongoing patent disputes with Moderna and a slight cut to fiscal 2025 earnings estimates by Cantor Fitzgerald. Positive Sentiment: Xtandi plus leuprolide improved overall survival in men with non-metastatic hormone-sensitive prostate cancer in the Phase 3 EMBARK trial, bolstering Pfizer’s oncology franchise. Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study Positive Sentiment: Pfizer reported promising topline results for XTANDI® plus leuprolide in high-risk, non-metastatic prostate cancer, with no new safety concerns. XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes Positive Sentiment: An update on Pfizer’s ongoing Phase 3 COVID-19 treatment study suggests the therapy could be a potential game-changer in reducing severe disease. Pfizer’s New COVID-19 Treatment Study: A Potential Game Changer? Positive Sentiment: Early Phase 3 data from a migraine study indicate potential benefits for young patients, supporting future label expansion. Pfizer’s Promising Migraine Study: A Potential Game-Changer for Young Patients Positive Sentiment: Interim findings from the abrocitinib pregnancy safety study showed reassuring outcomes, enhancing market confidence ahead of broader use. Pfizer’s Abrocitinib Pregnancy Study: Safety Insights and Market Impact Positive Sentiment: Post-marketing data for the senior-focused Abrysvo vaccine study confirmed a favorable safety profile in older adults. Pfizer’s Abrysvo Study: Ensuring Safety for Seniors Positive Sentiment: A Phase 3 pediatric migraine trial for rimegepant showed strong tolerability, potentially opening a new pediatric indication. Pfizer’s Rimegepant Study: A Potential Game-Changer for Pediatric Migraine Treatment Positive Sentiment: Early Phase 1 data on PF-07985045, a novel oncology candidate, demonstrated favorable pharmacokinetics, supporting further development. Pfizer’s New Study on PF-07985045: A Potential Game-Changer in Cancer Treatment Positive Sentiment: Real-world evidence for abrocitinib in atopic dermatitis highlighted strong market uptake potential ahead of label expansions. Pfizer’s Real-World Study on Abrocitinib for Atopic Dermatitis: Market Implications Positive Sentiment: A Phase I trial of mevrometostat showed favorable safety signals, underpinning its potential as a novel cancer therapy. Pfizer’s Mevrometostat Study: A Potential Game-Changer in Cancer Treatment Positive Sentiment: Post-marketing surveillance for Cibinqo underlined its market potential in chronic inflammatory diseases. Pfizer’s Cibinqo Study: A Closer Look at Its Market Potential Neutral Sentiment: The stock is trading up about 1.7% on increased volume, prompting questions on valuation and buy-the-dip opportunities. Pfizer (NYSE:PFE) Trading Up 1.7% - Should You Buy? Neutral Sentiment: Analysts preview expectations ahead of the upcoming Q2 earnings report, highlighting both revenue drivers and margin pressures. Pfizer Earnings Preview: What to Expect Neutral Sentiment: Industry reports note Pfizer among firms expanding into the “cannabis light” market, a segment with nascent regulatory clarity. Companies Like Pfizer Inc (PFE) are Boosting the Cannabis Light Market Negative Sentiment: Pfizer and BioNTech appealed to the UK Court of Appeal to overturn a ruling that their COVID-19 vaccine infringes a Moderna patent, extending legal uncertainty. Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win Negative Sentiment: Cantor Fitzgerald cut its FY 2025 EPS estimate for Pfizer slightly to $3.09 from $3.10, reflecting moderating margin expectations. Pfizer FY2025 EPS Forecast Decreased by Cantor Fitzgerald Negative Sentiment: A comparative analysis argues Johnson & Johnson’s growth outlook and Innovative Medicine segment may outpace Pfizer in 2025, putting competitive pressure on valuation. JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now? Posted 50m agoAI Generated. May Contain Errors. PFE Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study2 hours ago | benzinga.comPfizer (NYSE:PFE) Trading Up 1.7% - Should You Buy?4 hours ago | marketbeat.comPfizer’s New COVID-19 Treatment Study: A Potential Game Changer?5 hours ago | tipranks.comPfizer’s Promising Migraine Study: A Potential Game-Changer for Young Patients5 hours ago | tipranks.comPfizer’s Abrocitinib Pregnancy Study: Safety Insights and Market Impact5 hours ago | tipranks.comPfizer’s Abrysvo Study: Ensuring Safety for Seniors5 hours ago | tipranks.comPfizer’s Rimegepant Study: A Potential Game-Changer for Pediatric Migraine Treatment5 hours ago | tipranks.comPfizer’s New Study on PF-07985045: A Potential Game-Changer in Cancer Treatment?5 hours ago | tipranks.comPfizer’s Pediatric Migraine Study: A Potential Game-Changer for Rimegepant5 hours ago | tipranks.comPfizer’s Real-World Study on Abrocitinib for Atopic Dermatitis: Market Implications5 hours ago | tipranks.comPfizer’s Mevrometostat Study: A Potential Game-Changer in Cancer Treatment5 hours ago | tipranks.comPfizer’s Cibinqo Study: A Closer Look at Its Market Potential5 hours ago | tipranks.comCode Waechter LLC Buys Shares of 13,226 Pfizer Inc. (NYSE:PFE)July 10 at 9:30 AM | marketbeat.comPfizer (PFE) and BioNTech Appeal Patent Ruling Favoring ModernaJuly 10 at 9:05 AM | gurufocus.comPfizer FY2025 EPS Forecast Decreased by Cantor FitzgeraldJuly 10 at 8:41 AM | marketbeat.comPfizer (NYSE:PFE) HeadlineJuly 10 at 8:21 AM | gurufocus.comPfizer (PFE) Announces Positive Results from Prostate Cancer Drug Study | PFE Stock NewsJuly 10 at 8:21 AM | gurufocus.comPfizer, Astellas say Xtandi regimen hit secondary goal in late-stage trial for prostate cancerJuly 10 at 8:21 AM | seekingalpha.comPfizer, BioNTech challenge Moderna’s COVID vaccine patent win in U.K.July 10 at 8:21 AM | seekingalpha.comPfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent winJuly 10 at 7:18 AM | reuters.comPfizer Inc. (NYSE:PFE) Shares Sold by Lbp Am SaJuly 10 at 7:07 AM | marketbeat.comAxxcess Wealth Management LLC Sells 31,881 Shares of Pfizer Inc. (NYSE:PFE)July 10 at 7:06 AM | marketbeat.comXTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical RecurrenceJuly 10 at 6:45 AM | businesswire.comEU official Ursula von der Leyen comfortably survives a confidence voteEuropean Commission President Ursula von der Leyen has comfortably survived a vote of no confidence...July 10 at 6:12 AM | marketbeat.comBrown Advisory Inc. Sells 117,326 Shares of Pfizer Inc. (NYSE:PFE)July 10 at 5:28 AM | marketbeat.comPfizer Earnings Preview: What to ExpectJuly 9 at 6:59 PM | msn.comPfizer’s New Pediatric Study on Abrocitinib: A Potential Game-Changer for Eczema TreatmentJuly 9 at 12:16 PM | tipranks.comPfizer’s Migraine Study: A Potential Game-Changer for Investors?July 9 at 12:16 PM | tipranks.comPfizer’s Latest Study on COVID-19 and Influenza: Key Insights for InvestorsJuly 9 at 12:16 PM | tipranks.comPfizer’s Rimegepant Pregnancy Study: Key Insights for InvestorsJuly 9 at 12:16 PM | tipranks.comPfizer’s Latest Study on COVID-19 Vaccine Effectiveness: What Investors Need to KnowJuly 9 at 12:16 PM | tipranks.comPfizer’s New Phase 1 Trial: A Potential Game Changer in Cancer Treatment?July 9 at 12:16 PM | tipranks.comPfizer’s ATGAM Study: A Key Update for InvestorsJuly 9 at 12:16 PM | tipranks.comPfizer’s Vizimpro Study: Key Insights for InvestorsJuly 9 at 12:16 PM | tipranks.comPfizer’s Gene Therapy Trial for Duchenne Muscular Dystrophy: A Market Game-Changer?July 9 at 12:16 PM | tipranks.comPfizer’s Inclacumab Study: A Promising Step for Sickle Cell Disease TreatmentJuly 9 at 12:16 PM | tipranks.comNisa Investment Advisors LLC Sells 354,629 Shares of Pfizer Inc. (NYSE:PFE)July 9 at 10:13 AM | marketbeat.comMoloney Securities Asset Management LLC Boosts Stock Holdings in Pfizer Inc. (NYSE:PFE)July 9 at 9:45 AM | marketbeat.comPfizer Inc. (NYSE:PFE) Shares Sold by Rehmann Capital Advisory GroupJuly 9 at 9:00 AM | marketbeat.comChemung Canal Trust Co. Cuts Position in Pfizer Inc. (NYSE:PFE)July 9 at 8:37 AM | marketbeat.comGreenleaf Trust Purchases 16,267 Shares of Pfizer Inc. (NYSE:PFE)July 9 at 8:01 AM | marketbeat.comPfizer Inc. (NYSE:PFE) Shares Purchased by CORDA Investment Management LLC.July 9 at 7:42 AM | marketbeat.comNew Insight Wealth Advisors Buys New Shares in Pfizer Inc. (NYSE:PFE)July 9 at 7:32 AM | marketbeat.comStratos Wealth Partners LTD. Has $6.66 Million Position in Pfizer Inc. (NYSE:PFE)July 9 at 6:45 AM | marketbeat.comStratos Wealth Advisors LLC Increases Stock Holdings in Pfizer Inc. (NYSE:PFE)July 9 at 6:28 AM | marketbeat.comPekin Hardy Strauss Inc. Trims Stake in Pfizer Inc. (NYSE:PFE)July 9 at 6:08 AM | marketbeat.comCompanies Like Pfizer Inc (PFE) are Boosting the Cannabis Light MarketJuly 9 at 4:56 AM | msn.comPfizer (NYSE:PFE) Shares Up 2.7% - Still a Buy?July 8 at 2:41 PM | marketbeat.comPfizer restructures executive team as reputation chief departs - BloombergJuly 8 at 1:53 PM | investing.comPfizer’s Pediatric Migraine Study: A Potential Game-Changer for RimegepantJuly 8 at 12:37 PM | tipranks.com Get Pfizer News Delivered to You Automatically Sign up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter. Email Address PFE Media Mentions By Week PFE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PFE News Sentiment▼0.950.56▲Average Medical News Sentiment PFE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PFE Articles This Week▼10866▲PFE Articles Average Week Get Pfizer News Delivered to You Automatically Sign up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Amgen News Gilead Sciences News Moderna News Novavax News Viatris News AbbVie News Bristol Myers Squibb News Johnson & Johnson News Eli Lilly and Company News Merck & Co., Inc. News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:PFE) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pfizer Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pfizer With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.